These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://sabrinawqlz093672.wizzardsblog.com/39111421/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide